Physician profile
Sarah Ballinger
NPI 1538684857
$2,919.93
in general payments reported to CMS, 2019-2025
38 companies · $654 in 2025
The $654 reported for 2025 was more than what 78% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $308 · 2022: $603 · 2023: $666 · 2024: $689 · 2025: $654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,909 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,909.01 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $287.40 | 2021-2025 | |
| Celgene Corporation | $286.83 | 2021-2025 | Reblozyl, Opdualag, Pomalyst |
| Janssen Biotech, INC. | $235.85 | 2022-2025 | Tecvayli, Talvey, Darzalex |
| Deciphera Pharmaceuticals INC. | $224.87 | 2021-2025 | Qinlock, Romvimza, Tgct |
| Pfizer INC. | $196.26 | 2021-2025 | |
| Genzyme Corporation | $132.17 | 2023-2024 | |
| Abbvie INC. | $131.62 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $107.41 | 2021-2025 | Opdivo |
| Astellas Pharma US INC | $104.25 | 2022-2025 | Vyloy |
| Pharmacyclics LLC, An Abbvie Company | $102.39 | 2021-2023 | Imbruvica |
| Merck Sharp & Dohme LLC | $89.69 | 2021-2025 | Reblozyl, Keytruda |
| Array Biopharma INC | $78.05 | 2024-2025 | Mektovi, Braftovi, Lorbrena |
| Gilead Sciences, INC. | $76.56 | 2023-2024 | Trodelvy |
| Tersera Therapeutics LLC | $68.02 | 2024-2025 | Zoladex |
| Glaxosmithkline, LLC. | $66.52 | 2022-2025 | Ojjaara |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $66.09 | 2023-2024 | Brukinsa, Tevimbra |
| Genentech USA, INC. | $58.81 | 2021-2024 | Polivy |
| Astrazeneca Pharmaceuticals LP | $50.90 | 2023-2025 | Imfinzi |
| Blueprint Medicines Corporation | $50.81 | 2022 | |
| Amgen INC. | $49.98 | 2021-2022 | |
| Puma Biotechnology, INC. | $45.27 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.80 | 2024 | |
| Kite Pharma, INC. | $43.18 | 2022-2023 | Yescarta |
| Seagen INC. | $34.49 | 2021-2022 | |
| Genmab U.S., INC. | $33.37 | 2023-2024 | Epkinly |
| Incyte Corporation | $30.38 | 2021 | |
| Sobi, INC | $23.44 | 2023 | |
| Springworks Therapeutics, INC. | $23.29 | 2025 | Ogsiveo |
| Sanofi US Services INC. | $22.96 | 2025 | |
| Daiichi Sankyo INC. | $20.07 | 2024 | Enhertu |
| Recordati_rare_diseases_inc. | $18.80 | 2024 | Sylvant |
| Coherus Oncology, INC. | $18.76 | 2022 | |
| Mirati Therapeutics, INC. | $18.34 | 2023 | Krazati |
| G1 Therapeutics, INC. | $17.59 | 2022 | |
| Eisai INC. | $17.42 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $17.19 | 2023 | Tazverik |
| Celltrion USA INC. | $14.15 | 2025 | Vegzelma |
| Cti Biopharma Corp. | $11.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Ballinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.